Bristol Myers Squibb’s Opdivo and Yervoy combination shows unprecedented 10-year survival benefits in advanced melanoma

Bristol Myers Squibb has presented groundbreaking 10-year follow-up data from its CheckMate -067 trial, which highlights the long-term survival benefits of the Opdivo (nivolumab) and ... Read More